SCRS Resource Guide Network

Sites, Sponsors, CROs: Discover the solutions your clinical research teams need with SCRS.


We are uniting science, technology and talent to get ahead of disease together.


GSK is a fully focused biopharma company. We prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease. At the heart of this is our R&D focus on the science of the immune system, human genetics, genomics and advanced technologies, and our world-leading capabilities in vaccines and medicines development. We focus on four therapeutic areas: infectious diseases, HIV, respiratory/immunology, and oncology,

GSK press releasesGSK press releases 
  • Blenrep (belantamab mafodotin) combinations in multiple myeloma application accepted for review by the European Medicines Agency July 19, 2024 2:08am

    Regulatory submission supported by phase III head-to-head DREAMM-7 and DREAMM-8 trials
    View this post

  • ViiV Healthcare to announce data from largest head-to-head randomised clinical trial for 2-drug regimen Dovato against 3-drug regimen Biktarvy at AIDS 2024 July 15, 2024 5:06am

    The presentation is one of 25 abstracts evaluating the company’s portfolio of marketed HIV treatment and prevention options.
    View this post

  • Brazil and Thailand become first malaria-endemic countries to launch new single-dose radical cure medicine to prevent the relapse of Plasmodium vivax malaria July 5, 2024 5:00am

    Launch of single-dose tafenoquine, co-administered with chloroquine, is another step closer to global elimination of malaria.
    View this post

  • GSK and CureVac to restructure collaboration into new licensing agreement July 3, 2024 1:02pm

    GSK acquires full rights to develop, manufacture and commercialise globally mRNA candidate vaccines for influenza and COVID-19.
    View this post

  • Statement: Zantac (ranitidine) litigation – Gross case June 28, 2024 8:38am

    GSK has reached a confidential settlement with Martin Gross resolving the case he filed
    View this post

  • Statement: US Centers for Disease Control and Prevention’s Advisory Committee on Immunisation Practices updates recommendations on adult RSV vaccines ahead of the next season June 26, 2024 3:29pm

    GSK today announced that the US CDC ACIP voted in favour of recommending the routine use of RSV vaccines in all adults aged 75 and above.
    View this post

Web Site: www.gsk.com 


  • GlaxoSmithKline
    Pharmaceutical Manufacturing
    980 Great West Road
    United States
    Map It »
  • Videos4
  • News6
  • Last UpdatedJuly 24, 2023 12:39pm EDT